Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 04 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-2.47 Insider Own56.54% Shs Outstand41.80M Perf Week-9.95%
Market Cap286.67M Forward P/E- EPS next Y-2.26 Insider Trans0.00% Shs Float18.35M Perf Month124.09%
Income-103.21M PEG- EPS next Q-0.74 Inst Own30.92% Short Float7.48% Perf Quarter59.76%
Sales32.57M P/S8.80 EPS this Y7.83% Inst Trans-0.31% Short Ratio8.21 Perf Half Y-10.30%
Book/sh-1.36 P/B- EPS next Y6.59% ROA-27.62% Short Interest1.37M Perf Year12.79%
Cash/sh6.16 P/C1.10 EPS next 5Y- ROE-470.38% 52W Range2.70 - 9.97 Perf YTD5.27%
Dividend Est.- P/FCF- EPS past 5Y-38.31% ROI- 52W High-31.90% Beta3.17
Dividend TTM- Quick Ratio5.10 Sales past 5Y391.13% Gross Margin75.42% 52W Low151.48% ATR (14)0.80
Dividend Ex-Date- Current Ratio5.10 EPS Y/Y TTM8.50% Oper. Margin-351.04% RSI (14)56.98 Volatility13.35% 16.31%
Employees161 Debt/Eq- Sales Y/Y TTM106.70% Profit Margin-316.87% Recom1.40 Target Price13.75
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q44.81% Payout- Rel Volume1.19 Prev Close7.94
Sales Surprise281.38% EPS Surprise51.43% Sales Q/Q163.46% EarningsNov 02 BMO Avg Volume167.25K Price6.79
SMA2015.52% SMA5026.66% SMA20011.60% Trades Volume198,351 Change-14.48%
Date Action Analyst Rating Change Price Target Change
Mar-28-23Initiated BofA Securities Buy $10
Jan-05-23Initiated BMO Capital Markets Outperform $20
Nov-22-21Initiated H.C. Wainwright Buy $25
Nov-17-20Initiated Wedbush Outperform $24
Nov-17-20Initiated Morgan Stanley Overweight $24
Nov-17-20Initiated Goldman Buy $27
Nov-17-20Initiated Cowen Outperform
Feb-28-24 07:00AM
Feb-12-24 02:43AM
Feb-09-24 10:02AM
Feb-08-24 07:00AM
Jan-09-24 08:44AM
07:00AM Loading…
Jan-08-24 07:00AM
Jan-03-24 04:05PM
Dec-26-23 12:00PM
Dec-11-23 09:55AM
Dec-01-23 07:00AM
Nov-27-23 07:01PM
Nov-21-23 06:00AM
Nov-03-23 06:12AM
07:00AM Loading…
Nov-02-23 07:00AM
Nov-01-23 10:30AM
Oct-24-23 08:00AM
Oct-19-23 10:30AM
Oct-13-23 08:00AM
Oct-04-23 08:00AM
Oct-02-23 07:00AM
Sep-27-23 08:31AM
Sep-11-23 06:30AM
Sep-05-23 08:00AM
Aug-31-23 07:00AM
Aug-29-23 09:00AM
Aug-11-23 03:54PM
Aug-08-23 07:00AM
Aug-04-23 08:15AM
07:00AM Loading…
Jul-09-23 07:58PM
Jun-28-23 01:44PM
Jun-07-23 08:00AM
Jun-06-23 07:56AM
Jun-05-23 07:00AM
May-16-23 06:00AM
May-10-23 07:47AM
May-08-23 08:15AM
Apr-27-23 04:35AM
Apr-25-23 04:05PM
Apr-24-23 01:28PM
Apr-10-23 04:05PM
Apr-06-23 04:05PM
Mar-26-23 08:14AM
Mar-09-23 08:35AM
Mar-01-23 08:00AM
Feb-16-23 01:49PM
Jan-09-23 07:00AM
Dec-21-22 05:19AM
Dec-05-22 07:00AM
Nov-22-22 08:00AM
Nov-14-22 07:00AM
Nov-10-22 05:18AM
Nov-09-22 07:00AM
Nov-08-22 08:15AM
Oct-27-22 07:00AM
Oct-26-22 09:55AM
Oct-20-22 07:00AM
Oct-16-22 10:45AM
Sep-27-22 08:00AM
Sep-01-22 04:05PM
Aug-31-22 04:05PM
Aug-25-22 06:27AM
Aug-24-22 09:57AM
Aug-23-22 11:31AM
Aug-17-22 07:00AM
Aug-09-22 08:25AM
Aug-01-22 08:00AM
Jun-23-22 07:41AM
May-31-22 04:05PM
May-26-22 11:03AM
May-20-22 11:51AM
May-19-22 04:01PM
May-09-22 07:00AM
Apr-13-22 11:30AM
Apr-01-22 08:00AM
Mar-23-22 07:46AM
Mar-18-22 10:00AM
Mar-11-22 04:01PM
Mar-10-22 07:00AM
Feb-28-22 04:05PM
Feb-15-22 10:05AM
Jan-12-22 10:00AM
Jan-11-22 10:00AM
Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Agresta SamuelChief Medical OfficerAug 16Option Exercise3.72311,2971,158,025311,297Aug 18 04:03 PM
Agresta SamuelChief Medical OfficerAug 16Sale8.25311,2972,568,2000Aug 18 04:03 PM